Diversified Healthcare Trust

DB:SNF Stock Report

Market Cap: €526.8m

Diversified Healthcare Trust Valuation

Is SNF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SNF (€2.17) is trading above our estimate of fair value (€1.13)

Significantly Below Fair Value: SNF is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNF?

Key metric: As SNF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SNF. This is calculated by dividing SNF's market cap by their current revenue.
What is SNF's PS Ratio?
PS Ratio0.4x
SalesUS$1.48b
Market CapUS$550.11m

Price to Sales Ratio vs Peers

How does SNF's PS Ratio compare to its peers?

The above table shows the PS ratio for SNF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.8x
HABA Hamborner REIT
4.8x-1.2%€510.8m
AOX alstria office REIT-AG
5.6x-1.5%€1.4b
DKG Deutsche Konsum REIT-AG
0.7x-45.3%€127.6m
GMRE Global Medical REIT
3.8x3.2%US$542.7m
SNF Diversified Healthcare Trust
0.4x5.8%€550.1m

Price-To-Sales vs Peers: SNF is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (3.8x).


Price to Sales Ratio vs Industry

How does SNF's PS Ratio compare vs other companies in the Global Health Care REITs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.6.7x0%
SNF Diversified Healthcare Trust
0.4x5.8%US$550.11m
SNF 0.4xIndustry Avg. 6.7xNo. of Companies8PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.6.7x0%
SNF Diversified Healthcare Trust
0.4x39.5%US$550.11m
No more companies

Price-To-Sales vs Industry: SNF is good value based on its Price-To-Sales Ratio (0.4x) compared to the Global Health Care REITs industry average (6.7x).


Price to Sales Ratio vs Fair Ratio

What is SNF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: SNF is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.17
€3.31
+52.4%
42.9%€4.73€1.89n/a2
Dec ’25€2.39
€3.31
+38.8%
42.9%€4.73€1.89n/a2
Nov ’25€3.19
€4.16
+30.4%
33.3%€5.55€2.77n/a2
Oct ’25€3.71
€3.59
-3.1%
50.0%€5.39€1.80n/a2
Sep ’25€3.16
€3.65
+15.4%
50.0%€5.48€1.83n/a2
Jul ’25€2.75
€3.25
+17.9%
42.9%€4.64€1.85n/a2
Jun ’25€2.19
€3.25
+48.1%
42.9%€4.64€1.85n/a2
May ’25€2.17
€3.29
+51.2%
42.9%€4.69€1.88n/a2
Apr ’25€2.29
€3.22
+40.4%
42.9%€4.60€1.84n/a2
Oct ’24€1.79
€2.51
+40.7%
66.7%€4.19€0.84€3.712
Sep ’24€2.39
€2.28
-4.5%
60.0%€3.65€0.91€3.162
Aug ’24€1.88
€1.86
-1.0%
50.0%€2.79€0.93€2.982
Jul ’24€2.02
€1.86
-7.8%
50.0%€2.79€0.93€2.752
Jun ’24€1.33
€1.86
+40.3%
50.0%€2.79€0.93€2.192
May ’24€0.82
€1.29
+56.7%
68.1%€2.51€0.46€2.173
Apr ’24€1.25
€1.72
+38.2%
98.8%€4.66€0.47€2.294
Mar ’24€0.91
€1.60
+76.1%
95.7%€4.23€0.47€2.924
Feb ’24€0.65
€1.60
+144.5%
95.7%€4.23€0.47€2.614
Jan ’24€0.59
€1.65
+178.6%
91.5%€4.24€0.47€3.354
Dec ’23€0.95
€1.94
+103.4%
77.1%€4.35€0.48€2.384

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diversified Healthcare Trust is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew BabinBaird
Joshua DennerleinBofA Global Research
Bryan MaherB. Riley Securities, Inc.